The role of preoperative aspartate aminotransferase-to-platelet ratio index in predicting complications following total hip arthroplasty.
APRI
Cirrhosis
Complication
Liver damage
Osteoarthritis
Total hip arthroplasty
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
02 Dec 2023
02 Dec 2023
Historique:
received:
24
07
2023
accepted:
25
11
2023
medline:
4
12
2023
pubmed:
3
12
2023
entrez:
2
12
2023
Statut:
epublish
Résumé
The purpose of this study was to investigate the relationship between preoperative aspartate aminotransferase-to-platelet ratio index (APRI) and postoperative complications following total hip arthroplasty (THA). All THA for osteoarthritis patients from 2007 to 2020 within the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database were included in this study. Subjects were subsequently divided into cohorts based on APRI. Four groups, including normal range, some liver damage, significant fibrosis, and cirrhosis groups, were created. Comparisons between groups were made for demographics, past medical history, and rate of major and minor complications. Other outcomes included readmission, reoperation, discharge destination, mortality, periprosthetic fracture, and postoperative hip dislocation. Multivariate logistic regression analysis was performed to determine the role of preoperative APRI in predicting adverse outcomes. Statistical significance was set at p < 0.05. In total, 104,633 primary THA patients were included in this study. Of these, 103,678 (99.1%) were in the normal APRI group, 444 (0.4%) had some liver damage, 256 (0.2%) had significant fibrosis, and 253 (0.2%) had cirrhosis. When controlling for demographics and relevant past medical history, the abnormal APRI groups had a significantly higher likelihood of major complication, minor complication, intraoperative or postoperative bleeding requiring transfusion, readmission, and non-home discharge (all p < 0.05) compared to normal APRI individuals. Abnormal preoperative APRI is linked with an increasing number of adverse outcomes following THA for osteoarthritis for patients across the United States. Level I.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of this study was to investigate the relationship between preoperative aspartate aminotransferase-to-platelet ratio index (APRI) and postoperative complications following total hip arthroplasty (THA).
METHODS
METHODS
All THA for osteoarthritis patients from 2007 to 2020 within the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database were included in this study. Subjects were subsequently divided into cohorts based on APRI. Four groups, including normal range, some liver damage, significant fibrosis, and cirrhosis groups, were created. Comparisons between groups were made for demographics, past medical history, and rate of major and minor complications. Other outcomes included readmission, reoperation, discharge destination, mortality, periprosthetic fracture, and postoperative hip dislocation. Multivariate logistic regression analysis was performed to determine the role of preoperative APRI in predicting adverse outcomes. Statistical significance was set at p < 0.05.
RESULTS
RESULTS
In total, 104,633 primary THA patients were included in this study. Of these, 103,678 (99.1%) were in the normal APRI group, 444 (0.4%) had some liver damage, 256 (0.2%) had significant fibrosis, and 253 (0.2%) had cirrhosis. When controlling for demographics and relevant past medical history, the abnormal APRI groups had a significantly higher likelihood of major complication, minor complication, intraoperative or postoperative bleeding requiring transfusion, readmission, and non-home discharge (all p < 0.05) compared to normal APRI individuals.
CONCLUSIONS
CONCLUSIONS
Abnormal preoperative APRI is linked with an increasing number of adverse outcomes following THA for osteoarthritis for patients across the United States.
LEVEL OF EVIDENCE
METHODS
Level I.
Identifiants
pubmed: 38042799
doi: 10.1186/s12891-023-07063-9
pii: 10.1186/s12891-023-07063-9
pmc: PMC10693101
doi:
Substances chimiques
Aspartate Aminotransferases
EC 2.6.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
934Informations de copyright
© 2023. The Author(s).
Références
JB JS Open Access. 2023 Feb 28;8(1):
pubmed: 36864906
J Clin Gastroenterol. 2019 Oct;53(9):e356-e361
pubmed: 30001287
J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460
pubmed: 30180053
Eurasian J Med. 2008 Apr;40(1):18-24
pubmed: 25610017
Ann Gastroenterol. 2017;30(5):486-497
pubmed: 28845103
Arthroplast Today. 2021 Feb 23;8:11-14
pubmed: 33665276
J Am Acad Orthop Surg. 2023 Mar 15;31(6):292-299
pubmed: 36728666
BMC Gastroenterol. 2012 Feb 14;12:14
pubmed: 22333407
SICOT J. 2019;5:40
pubmed: 31674904
J Clin Neurosci. 2022 Oct;104:69-73
pubmed: 35981462
J Arthroplasty. 2021 Apr;36(4):1361-1366.e1
pubmed: 33121848
Hepatology. 2015 Jan;61(1):292-302
pubmed: 25132233
Hepat Mon. 2011 Feb;11(2):103-6
pubmed: 22087126
J Arthroplasty. 2020 Jun;35(6):1508-1515.e2
pubmed: 32113812
J Bone Joint Surg Am. 2015 Sep 2;97(17):1386-97
pubmed: 26333733
J Transl Int Med. 2018 Mar 28;6(1):38-42
pubmed: 29607303
Arthroplast Today. 2021 Jul 05;10:18-23
pubmed: 34277906
Hepatology. 2011 Mar;53(3):726-36
pubmed: 21319189
J Orthop. 2017 Jan 04;14(1):171-175
pubmed: 28070149
Health Technol Assess. 2015 Jan;19(9):1-409, v-vi
pubmed: 25633908
Acta Orthop. 2015 Feb;86(1):108-13
pubmed: 25238440
Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):189-196
pubmed: 29263732
JAMA Netw Open. 2023 Jan 3;6(1):e2253942
pubmed: 36719679
Eur J Vasc Endovasc Surg. 2021 Jun;61(6):964-970
pubmed: 33773904
Orthopedics. 1999 Feb;22(2):185-9
pubmed: 10037332
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1158-1163
pubmed: 34230107
World J Gastroenterol. 1999 Aug;5(4):301-304
pubmed: 11819452